co.don AG Logo

co.don AG

Develops personalized cartilage cell transplants for minimally invasive joint repair.

CNW | F

Overview

Corporate Details

ISIN(s):
DE000A3E5C08 (+1 more)
LEI:
3912006R73YW0SX1KG21
Country:
Germany
Address:
Warthestr. 21, 14513 Teltow
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

co.don AG is a biopharmaceutical company specializing in tissue engineering and regenerative medicine. The company focuses on the development, manufacturing, and marketing of autologous cell therapies for the treatment of articular cartilage defects. Its core process involves using a patient's own cartilage cells (chondrocytes) to produce personalized cell transplants, such as spherical cartilage cell implants (spheroids), for the minimally invasive repair of joints. Following an asset purchase in early 2023, the operative business was taken over by an investor and now operates as CO.DON GmbH, a ReLive company, continuing its work in human cell-based therapies.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-09-30 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2022 bis zum 30.0…
German 142.4 KB
2022-09-29 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2022 bis zum 30.06.2022
German 6.4 KB
2022-07-11 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2021 bis zum 31.12.2021
German 1.3 MB
2022-07-06 00:00
Report Publication Announcement
Berichtigung der Veröffentlichung vom 14.06.2022
German 6.4 KB
2022-06-14 00:00
Report Publication Announcement
Berichtigt am 06.07.2022
German 6.4 KB
2022-04-29 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2021 bis zum 31.12.2021
German 6.4 KB
2021-09-11 00:00
Director's Dealing
CO.DON AG: Mitteilung über Eigengeschäfte von Führungskräften gem. Art. 19 MAR
German 13.9 KB
2021-08-30 00:00
Interim Report
Halbjahresfinanzbericht
German 148.6 KB
2021-05-27 00:00
Report Publication Announcement
Jahresabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-25 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2020 bis zum 31.12.2020
German 4.2 KB
2021-05-22 00:00
Regulatory News Service
Ad-hoc-Meldung gemäß Art. 17 MAR in Verbindung mit § 4 Abs. 1 S. 1 Nr. 1a WpAV
English 11.8 KB
2020-08-28 00:00
Interim Report
Datum:28.08.2020
German 381.2 KB
2020-08-24 00:00
Report Publication Announcement
Datum:24.08.2020
German 12.2 KB
2020-07-28 00:00
Annual Report
Datum:28.07.2020
German 998.8 KB
2020-07-07 00:00
Annual Report
Datum:07.07.2020
German 41.3 KB

Automate Your Workflow. Get a real-time feed of all co.don AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for co.don AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for co.don AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2021-10-21 Günther, Bernd Supervisory board Buy None 35.84 EUR
2021-10-20 Laik, Robin Board Other None 10,348,300.00 EUR
2021-10-20 ELBER GmbH Close relation Other None 10,179,000.00 EUR
2021-10-20 Rofalski, Volker Supervisory board Other None 292,500.00 EUR
2021-10-20 Müller, Dr. Axel Supervisory board Other None 195,000.00 EUR
2021-10-20 Laumann, Johannes Board Other None 131,625.00 EUR
2021-10-20 Laik, Louisa Close relation Other None 129,987.00 EUR
2021-10-20 Laik, Daniel Close relation Other None 97,500.00 EUR
2021-10-20 Friedrich, Neela Close relation Other None 64,993.50 EUR
2021-10-20 Schleede, Dr. Kristian Board Other None 29,250.00 EUR

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.